Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) is a global medical technology company whose news flow centers on hospital technologies, plasma collection systems and blood center products. Company communications describe a focus on improving the quality, effectiveness and efficiency of health care, so news items often highlight developments that affect these areas.
Investors following HAE news can expect regular announcements about quarterly financial results, including the availability of earnings releases and details for conference calls and webcasts with investors and analysts. These updates are typically accompanied by Form 8-K filings that furnish the related press releases and summarize results for specific fiscal quarters.
Haemonetics also issues news about its participation in healthcare investment conferences, such as presentations at the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events provide additional context for the company’s strategy and operations in the medical technology space.
A notable category of news involves corporate transactions and interventional technologies. For example, Haemonetics announced the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation percutaneous vessel closure technology. Press releases describe how Vivasure’s PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore arterial and venous closure, is intended to expand Haemonetics’ range of closure devices and its presence in the large-bore closure market.
By monitoring the Haemonetics news page, readers can track earnings communications, conference participation, regulatory and acquisition-related updates, and other material events disclosed through press releases and SEC filings. This provides a consolidated view of developments affecting HAE within the surgical and medical instrument manufacturing industry.
Vivasure Medical has announced two significant regulatory milestones for its PerQseal® Elite vascular closure system. The company has submitted a Premarket Approval (PMA) application to the FDA for arterial procedures and received European CE mark approval for expanded indication covering large-bore venous closure.
PerQseal Elite is positioned as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure. The system features a unique inside-vessel deployment mechanism and requires no pre-procedure steps, offering advantages over conventional closure techniques that leave behind materials like collagen, metal implants, or sutures.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its fourth quarter and fiscal year 2025 financial results, which ended March 29, 2025, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on May 8, 2025, at 8:00 a.m. ET to discuss the results.
The company has provided access to supplemental materials including the earnings release and tables supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance. A replay of the conference call will be available for one year starting May 8, 2025, at 11:00 a.m. ET.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.
Haemonetics (NYSE: HAE) has scheduled the release of its fourth quarter and fiscal year 2025 financial results for May 8, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start time. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting May 8, 2025, at 11:00 am ET.
Haemonetics (NYSE: HAE) announced key executive leadership updates. Frank Chan, Ph.D. will join as Executive Vice President, Chief Operating Officer on April 7, 2025, while Roy Galvin has been appointed Executive Vice President, Chief Commercial Officer with immediate effect.
Chan, bringing over 25 years of medical device and healthcare technology leadership experience, will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations. He joins from Medtronic plc, where he served as President of Acute Care & Monitoring.
Galvin, who joined Haemonetics in 2022 as President, Global Plasma and Blood Center, will now expand his responsibilities to include the Global Hospital business, directing all commercialization initiatives across the company's full product portfolio. He brings over 25 years of experience from Medtronic plc in the Neuroscience and Orthopedic markets.
Haemonetics (NYSE: HAE) has announced its participation in the upcoming Raymond James 46th Annual Institutional Investors Conference. Chris Simon, President and CEO, will engage in a fireside chat with investors on Tuesday, March 4, 2025, at 2:50 p.m. ET.
The event will be accessible to the public through a live webcast on Haemonetics' Investor Relations website and via a dedicated link. Following the presentation, a replay will be made available approximately 12 hours after the event and will remain accessible for 90 days through the company's Investor Relations website.
Haemonetics (NYSE: HAE) has announced the availability of its third quarter fiscal year 2025 financial results for the period ended December 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on February 6, 2025, at 8:00 a.m. ET to discuss the results.
Participants can access the teleconference through registration and will receive a dial-in number with a personalized PIN. A live webcast is also available on Haemonetics' investor relations website. The company has posted the earnings release that will be referenced during the call on their website. A replay of the conference call and webcast will be accessible for one year starting February 6, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has completed the sale of its whole blood assets to GVS, S.p.A for a total consideration of up to $67.8 million. The deal includes $45.3 million upfront payment and potential earn-outs of up to $22.5 million over four years.
The transaction encompasses Haemonetics' whole blood collection, processing and filtration solutions portfolio, along with its Covina, California manufacturing facility and related assets in Tijuana, Mexico. The company plans to use the proceeds for general corporate purposes and growth initiatives.
Haemonetics will maintain its Blood Center business, continuing to manufacture and provide apheresis solutions for automated blood collection, including devices and disposable kits for platelets, plasma, and red cells collection.
Haemonetics (NYSE: HAE) has announced it will release its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with both the conference call and webcast replay accessible for one year starting February 6, 2025, at 11:00 am ET.